EQRx, CStone un­furl full lung can­cer da­ta for PD-L1 drug in what the part­ners are call­ing a first

As a self-styl­ized drug pric­ing dis­rup­tor, EQRx has high hopes for its lead PD-(L)1 to of­fer proof of con­cept for the en­tire busi­ness mod­el. Af­ter tout­ing a win back in May, the biotech is back with full da­ta in lung can­cer that could back up an ap­proval.

Pa­tients dosed with EQRx and CStone Phar­ma­ceu­ti­cals’ sug­e­mal­imab post­ed me­di­an pro­gres­sion-free sur­vival of 9 months com­pared with 5.8 months for pa­tients giv­en place­bo (p=0.0026), ac­cord­ing to full da­ta from the Phase III GEM­STONE-301 study in Stage III non-small cell lung can­cer set to be pre­sent­ed at this week­end’s #ES­MO21.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER